Hide metadata

dc.date.accessioned2015-11-30T16:01:27Z
dc.date.available2015-11-30T16:01:27Z
dc.date.created2015-11-23T14:13:14Z
dc.date.issued2015
dc.identifier.citationNygaard, Gro Owren Celius, Elisabeth Gulowsen de Rodez Benavent, Sigrid Aune Sowa, Piotr Gustavsen, Marte Wendel Fjell, Anders Martin Landrø, Nils Inge Walhovd, Kristine B Harbo, Hanne Flinstad . A longitudinal study of disability, cognition and gray matter atrophy in early multiple sclerosis patients according to evidence of disease activity. PLoS ONE. 2015, 10(8)
dc.identifier.urihttp://hdl.handle.net/10852/48115
dc.description.abstractNew treatment options may make “no evidence of disease activity” (NEDA: no relapses or disability progression and no new/enlarging MRI lesions, as opposed to “evidence of disease activity” (EDA) with at least one of the former), an achievable goal in relapsing-remitting multiple sclerosis (RRMS). The objective of the present study was to determine whether early RRMS patients with EDA at one-year follow-up had different disability, cognition, treatment and gray matter (GM) atrophy rates from NEDA patients and healthy controls (HC). RRMS patients (mean age 34 years, mean disease duration 2.2 years) were examined at baseline and one-year follow-up with neurological (n = 72), neuropsychological (n = 56) and structural MRI (n = 57) examinations. Matched HC (n = 61) were retested after three years. EDA was found in 46% of RRMS patients at follow-up. EDA patients used more first line and less second line disease modifying treatment than NEDA (p = 0.004). While the patients groups had similar disability levels at baseline, they differed in disability at follow-up (p = 0.010); EDA patients progressed (EDSS: 1.8–2.2, p = 0.010), while NEDA patients improved (EDSS: 2.0–1.7, p<0.001). Cognitive function was stable in both patient groups. Subcortical GM atrophy rates were higher in EDA patients than HC (p<0.001). These results support the relevance of NEDA as outcome in RRMS and indicate that pathological neurodegeneration in RRMS mainly occur in patients with evidence of disease activity.en_US
dc.languageEN
dc.language.isoenen_US
dc.publisherPublic Library of Science (PLoS)
dc.relation.ispartofNygaard, Gro Owren (2016) Cognition, disease activity and MRI changes in early multiple sclerosis. Doctoral thesis. http://urn.nb.no/URN:NBN:no-52721
dc.relation.urihttp://urn.nb.no/URN:NBN:no-52721
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleA longitudinal study of disability, cognition and gray matter atrophy in early multiple sclerosis patients according to evidence of disease activityen_US
dc.typeJournal articleen_US
dc.creator.authorNygaard, Gro Owren
dc.creator.authorCelius, Elisabeth Gulowsen
dc.creator.authorde Rodez Benavent, Sigrid Aune
dc.creator.authorSowa, Piotr
dc.creator.authorGustavsen, Marte Wendel
dc.creator.authorFjell, Anders Martin
dc.creator.authorLandrø, Nils Inge
dc.creator.authorWalhovd, Kristine B
dc.creator.authorHarbo, Hanne Flinstad
cristin.unitcode185,53,0,0
cristin.unitnameInstitutt for klinisk medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1292221
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=PLoS ONE&rft.volume=10&rft.spage=&rft.date=2015
dc.identifier.jtitlePLoS ONE
dc.identifier.volume10
dc.identifier.issue8
dc.identifier.doihttp://dx.doi.org/10.1371/journal.pone.0135974
dc.identifier.urnURN:NBN:no-52059
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn1932-6203
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/48115/2/journal.pone.0135974.pdf
dc.type.versionPublishedVersion
cristin.articleide0135974


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International